Fulcrum Therapeutics Inc (FULC)

NASDAQ
24.130
+0.660(+2.81%)
  • Volume:
    175,505
  • Bid/Ask:
    24.060/24.150
  • Day's Range:
    23.730 - 24.420

FULC Overview

Prev. Close
23.47
Day's Range
23.73-24.42
Revenue
15.24M
Open
23.42
52 wk Range
6.85-33.097
EPS
-2.48
Volume
175,505
Market Cap
922.57M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,444,151
P/E Ratio
-
Beta
-
1-Year Change
122.68%
Shares Outstanding
39,308,425
Next Earnings Date
Nov 17, 2021
What is your sentiment on Fulcrum Therapeutics Inc?
or
Vote to see community's results!

Fulcrum Therapeutics Inc News

Fulcrum Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellNeutralStrong Buy
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyNeutralSellStrong Buy

Fulcrum Therapeutics Inc Company Profile

Fulcrum Therapeutics Inc Company Profile

Employees
73

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Read More
  • BOING.
    0
    • Careful investors! The technology used by this company is old. This is not a good medium or long term investment; Better is: Crispr, Beam and Intellia.
      2
      • Do you not say the same thing about suppurt systems,,,word for word.
        0
      • Be careful with Bryan the shyster...
        0
    • price target 39$
      1
      • What the heck
        0
        • sell
          0
          • Keep or s?
            0
            • Any n??
              0
              • Any nws?
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.